Rutgers New Jersey Medical School (New York) — New York, New York

Public research footprint of Rutgers New Jersey Medical School (New York), compiled from the ClinicalTrials.gov public registry.

137

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma · Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 · Endometrial Clear Cell Adenocarcinoma · Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

Recently updated registry entries

NCT07061977 — Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation… (Recruiting)
NCT06575192 — Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast… (Recruiting)
NCT06058377 — Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment… (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Rutgers New Jersey Medical School (New York)?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 06, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.